A pharmacogenomics pilot found that nine out of ten patients carried genetic variation described as clinically relevant, according to The Pharmaceutical Journal. The outlet reported the finding on Tuesday, 6 October 2026.
Pharmacogenomics examines how a person's genetic makeup affects their response to medicines. A variant flagged as clinically relevant in this context suggests it could matter for how a drug is chosen or dosed, though the source summary does not detail which drugs or genes were involved.
The result points to how common such variation may be among patients tested in this kind of programme. The Pharmaceutical Journal did not publish further details in the material available, including the size of the pilot, where it ran, or how "clinically relevant" was defined.
The finding was reported as a headline figure from the pilot rather than as a completed clinical trial outcome. No information was given on whether patient care changed as a result of the testing, or on any follow-up.
What to watch next: whether fuller results from the pilot are released, including how many patients had testing acted upon and what effect that had on treatment.
